24 September 2026 · Medical Device Network
FDA panel backs Galleri multi-cancer detection test
Doctors & NHSMedical businessesRegulation & claims
An FDA panel has endorsed GRAIL’s Galleri multi-cancer early detection test. The panel voted 7–2 that the test’s benefits outweigh its risks.
Why it matters
The vote is relevant to clinicians and diagnostic businesses following risk–benefit scrutiny of early cancer detection technologies. The item reports a panel endorsement, not a final FDA approval.
Protect your practice
Summary for general information only — not legal, clinical or insurance advice.